2023 World Conference on Lung Cancer (Posters)-EP11.03. Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression

EP11.03. Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to compare the effectiveness of immunotherapy (ICI) monotherapy versus a combination of immunotherapy and chemotherapy (ICIChemo) in patients with metastatic non-small cell lung cancer (NSCLC) who had high PD-L1 expression. The study included 241 patients, with 133 receiving ICI monotherapy and 108 receiving ICIChemo. <br /><br />The analysis showed that there was a marginal difference in time to next treatment (TTNT) between the two treatment groups in the unadjusted analysis. However, after adjusting for relevant baseline clinical and demographic characteristics, the difference was no longer statistically significant. <br /><br />The adjusted progression-free survival (PFS) was numerically improved with ICIChemo compared to ICI, but the difference was not statistically significant. Similarly, the adjusted overall survival (OS) was numerically longer with ICIChemo, but again, the difference was not statistically significant.<br /><br />The study also examined patient characteristics and treatment patterns. The most common first-line (1L) regimens for both treatment groups were pembrolizumab and carboplatin-pembrolizumab-pemetrexed. Among patients who received second-line (2L) treatment, the most common regimens were carboplatin-pembrolizumab-pemetrexed and pembrolizumab.<br /><br />The study concludes that the addition of chemotherapy did not result in a statistically improved OS compared to ICI monotherapy alone. This finding may impact treatment patterns, considering the impact of chemotherapy on patient quality of life. The study suggests that future research with a longer follow-up time may provide more insights and a better understanding of the outcomes of these treatments.<br /><br />In summary, the study compared the outcomes of immunotherapy monotherapy versus a combination of immunotherapy and chemotherapy in patients with metastatic NSCLC. While there was a marginal difference in TTNT, the addition of chemotherapy did not significantly improve PFS or OS compared to immunotherapy alone.

Asset Subtitle

Kaushal Parikh

Meta Tag

Speaker Kaushal Parikh

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

immunotherapy monotherapy

combination therapy

ICI monotherapy

ICIChemo

metastatic non-small cell lung cancer

PD-L1 expression

time to next treatment

progression-free survival

overall survival

patient characteristics